2 completed, 1 active not recruiting, 1 enrolling by invitation. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Enrolling by invitation 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Glycomine, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label) - Phosphomannomutase 2 Deficiency, PMM2-CDG | Phase 2 / Phase 3 | Active not recruiting | Glycomine, Inc. | 50 | 2025-07-09 | 2026-08-14 |
| Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients GLM101 - Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 2 | Enrolling by invitation | Glycomine, Inc. | 90 | 2024-09-30 | 2026-10-23 |
| 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG GLM101 - Pmm2-CDG, Phosphomannomutase 2 Deficiency | Phase 2 | Completed | Glycomine, Inc. | 27 | 2022-11-29 | 2025-12-17 |
| Natural History Study Protocol in PMM2-CDG (CDG-Ia) Phosphomannomutase 2 Deficiency | Completed | Glycomine, Inc. | 139 | 2018-01-08 | 2026-07-08 |
Congenital disorder of glycosylation type 1A (4) · Ataxia (1)
Spain (4) · United States (4) · Czechia (3) · France (3) · Italy (3) · Portugal (3) · United Kingdom (3) · Belgium (2) · Germany (2) · Poland (2) · Netherlands (1)